If the title seems like science fiction, listen to this. Beka Solomon, a professor at Tel Aviv University, has found in mouse trials that filamentous phages, a harmless bacterial virus found almost everywhere from the depths of the ocean to the lining of the stomach, can be an effective treatment against Alzheimer’s disease when carried to the brain through the nose. Link here.
Solomon, working in this field for13 years after years of research in immunotherapy, figured if it isn’t possible to send drugs to the brain to treat Alzheimer’s disease the normal way because the blood-brain barrier prevents drugs from moving into the brain, then send them through the nose.
In mouse trials she found that filamentous phages, a harmless bacterial virus found almost everywhere from the depths of the ocean to the lining of the stomach, can be an effective treatment against Alzheimer’s disease when carried to the brain through the nose.
The cause of Alzheimer’s is believed to be plaque formation, which causes inflammation in the brain. Professor Solomon administered small doses of these phages through the nasal passages, which have a direct and rapid route to the brain. “There they lock onto the plaques associated with Alzheimer’s and dissolve them, reducing inflammation in the brain without any side effects. The body then gets rid of the waste naturally.”
Professor Solomon and her research team treated 150 mice with the phage for 12 months and “found the mice that had exhibited the symptoms of Alzheimer’s regained their sense of smell and also showed memory and cognitive improvement. After one year of treatment, they had 80 percent fewer plaques than untreated mice. The phages were eliminated from the brain and secreted from the body in urine and feces. The researchers saw no adverse effects in the peripheral organs – the kidneys, liver, lungs, and spleen biology were all normal. The mice showed very nice recovery of their cognitive function.”
The researcher presented her findings at a meeting of the American Society for Microbiology in Canada and believes further research is necessary but there is potential for a breakthrough.
A commercial department of Tel Aviv University is planning to commercialize this research and has licensed the technology to a startup company.
Just thought you’d like to know.
–Dr. Rohn Kessler
